The CCR approved 10 alternatives products from Apax Partners, BlackRock, Hamilton Lane, Partners Group, Kohlberg Kravis Roberts & Co., PineBridge and Warburg Pincus.
CCR Monthly Approval Report – April 2018
Lombard Odier led with 10 mutual funds registered in the month, while AZ Fund followed with three of its own products. Eleven other mutual funds managers and ETFs sponsors completed the list with one product each.
CCR Monthly Approval Report – March 2018
Evli led with nine funds registered in the month, while Goldman Sachs (2), Invesco (2), Schroder (1), Deutsche (1), BNY Mellon (1), Pictet (1), and Lyxor (1) won approval for their mutual fund products.
CCR Monthly Approval Report – February 2018
Deutsche, Nordea, and Acadian each had two of their mutual funds registered, while Investec, Nomura and Lyxor followed, each with one product approved.
Chilean AFPs make their first allocation to British manager Veritas
The Veritas Asian Fund, managed by Ezra Sun, invests in Asia (ex Japan) and its performance has shown great consistency. In 2017, it had a return of about 50%, undoubtedly catching the attention of AFPs.
Four alternatives managers now approved in the CCR
Intermediate Capital Group, Oaktree Capital Management, The Carlyle Group and Ardian got the go-ahead from the risk-rating commission to offer alternatives products to the AFPs.
CCR Monthly Approval Report – January 2018
Legg Mason, Invesco, Natixis, Lyxor, and Degroof Petercam were the managers registering products in January 2018.
New listings bring Deutsche’s ETF offering in Mexico to 30 products
"Deutsche is always looking for ways to provide investors efficient access to worldwide markets through strategies that best fit their investment needs, says Deutsche's Salvador Gomez.
With holy grail in reach, cross-border managers urge respect for process in Mexico
While preaching patience, Natixis's Mauricio Giordano told Fund Pro Latin America that Afores could potentially make their first cross-border-fund investments in the second half of 2018.
CCR Monthly Approval Report – December 2017
Products from HSBC, Lyxor, Aberdeen and others won approval, as did the first alternatives products from Carlyle Group, Oaktree Capital and Intermediate Capital Group.




